The Lantus vs Tresiba show in India: Winners both?
This article was originally published in Scrip
Premium priced Tresiba (insulin degludec), Novo Nordisk's ultra-long acting once-daily insulin, appears to have made striking gains in the basal analogues market in India – a segment dominated by Sanofi's Lantus (insulin glargine).
You may also be interested in...
Novo Nordisk’s new India managing director takes charge amid heightened competition in the diabetes space. The Danish firm stays committed to bringing new products to this market at a faster clip and all eyes will be on the launch trajectory of therapies like semaglutide.
Sanofi has launched its next generation basal insulin, Toujeo, on the Indian market at a significantly reduced per unit price point versus Novo Nordisk’s Tresiba (insulin degludec), setting the stage for an interesting market expansion battle.
The coronavirus pandemic has thrown up unprecedented challenges for the Indian clinical trials segment, as in other parts of the world. Experts tell Scrip how things are poised in the country including potential impact on some critical milestones, but efforts are underway to tackle the crisis.